We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis.
- Authors
Merli, Manuela; Lucidi, Cristina; Di Gregorio, Vincenza; Giannelli, Valerio; Giusto, Michela; Ceccarelli, Giancarlo; Riggio, Oliviero; Venditti, Mario
- Abstract
Background & Aims Bacterial infections are among the most common and life-threatening complications in cirrhosis. Qualitative and quantitative modifications of the gut microbiota, dysfunction of the intestinal barrier and multiple immune defects are factors that contribute to a pathological 'bacterial translocation' ( BT), leading to a higher susceptibility to infections in cirrhotic patients. Long-term therapies, commonly adopted in cirrhotic patients, may influence BT and modify the risk of infection in these patients. To investigate the influence of chronic therapies on the prevalence and microbiological characteristics of infections in cirrhosis. Methods Consecutive cirrhotic patients hospitalised from 2008 to 2013 were enrolled. All previous treatments were carefully recorded. Infections were actively sought out, patients were actively monitored for infection, and possible risk factors were evaluated. Results Four hundred cirrhotic patients were included. The most frequent therapies were proton pump inhibitors ( PPIs) (67%), non-absorbable-disaccharides (44%), beta-blockers ( BBs) (39%) and non-absorbable-antibiotics (10%). Child-Pugh C ( P < 0.001; OR 5; 95% CI: 2.6-9.9) and PPI therapy ( P = 0.008; OR 2; 95% CI: 1.2-3.2) were found to be independent predictors of infection, and the use of BBs was a protective factor ( P = 0.001; OR 0.46; 95% CI: 0.3-0.7). Cirrhotic patients with bacterial infection showed lower morbidity and mortality when taking BBs. Conclusions Proton pump inhibitors increase the risk of infection in cirrhosis and should not be prescribed in these patients without specific indications. In contrast, the use of BBs is associated with a lower rate of infection and attenuates the consequences of infections in cirrhotic patients.
- Subjects
ADRENERGIC beta blockers; CIRRHOSIS of the liver; BACTERIAL diseases; DISACCHARIDES; SEPSIS; PATIENTS
- Publication
Liver International, 2015, Vol 35, Issue 2, p362
- ISSN
1478-3223
- Publication type
Article
- DOI
10.1111/liv.12593